Cost-effectiveness analysis of trastuzum
β
Louis P. Garrison Jr; Deborah Lubeck; Deepa Lalla; Virginia Paton; Amylou Dueck;
π
Article
π
2007
π
John Wiley and Sons
π
English
β 209 KB
π 2 views
## Abstract ## BACKGROUND. Adding trastuzumab to adjuvant chemotherapy provides significant clinical benefit in patients with human epidermal growth factor receptor 2 (HER2)βpositive breast cancer. A costβeffectiveness analysis was performed to assess clinical and economic implications of adding t